Stock AZTA AZENTA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Azenta, Inc.

Equities

AZTA

US1143401024

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
52.18 USD +1.32% Intraday chart for Azenta, Inc. +3.02% -19.90%
Apr. 08 Transcript : Azenta, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM
Apr. 04 Evercore ISI Raises Azenta's Price Target to $60 From $64, Maintains In Line Rating MT

Valuation

Fiscal Period: Settembre 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,674 3,412 7,604 3,215 3,019 2,910 - -
Enterprise Value (EV) 1 2,674 3,412 7,426 3,215 3,019 2,910 2,910 2,910
P/E ratio 6.12 x 52.6 x 68.7 x 1.5 x -228 x -83.6 x -109 x 2,982 x
Yield 1.08% 0.86% 0.39% 0.23% - - - -
Capitalization / Revenue 3.42 x 3.8 x 6.37 x 5.79 x 4.54 x 4.13 x 3.92 x 3.69 x
EV / Revenue 3.42 x 3.8 x 6.37 x 5.79 x 4.54 x 4.13 x 3.92 x 3.69 x
EV / EBITDA 20.9 x 21.2 x 30.9 x 51.5 x 99.4 x 58.2 x 35.7 x 25 x
EV / FCF 39.9 x -1,658 x 78.4 x -5.96 x -138 x -115 x 303 x 77.6 x
FCF Yield 2.51% -0.06% 1.28% -16.8% -0.73% -0.87% 0.33% 1.29%
Price to Book 2.35 x 2.81 x 5.74 x 0.96 x 1.15 x 1.34 x 1.24 x 1.27 x
Nbr of stocks (in thousands) 72,224 73,760 74,297 75,020 60,154 55,765 - -
Reference price 2 37.03 46.26 102.4 42.86 50.19 52.18 52.18 52.18
Announcement Date 11/6/19 11/10/20 11/10/21 11/14/22 11/13/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Settembre 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 781.9 897.3 1,194 555.5 665.1 703.8 743.1 789.3
EBITDA 1 128.1 161 245.8 62.48 30.38 49.99 81.41 116.4
EBIT 1 90.74 122.4 180.5 28.45 -15.26 -5.82 23.45 54.65
Operating Margin 11.61% 13.64% 15.12% 5.12% -2.3% -0.83% 3.16% 6.92%
Earnings before Tax (EBT) 1 9.94 74.97 -48.97 -9.936 -30.43 -33.91 -15.75 19.61
Net income 1 437.8 64.85 110.7 2,133 -14.26 -27.47 -17.32 8.908
Net margin 55.99% 7.23% 9.28% 383.95% -2.14% -3.9% -2.33% 1.13%
EPS 2 6.050 0.8800 1.490 28.48 -0.2200 -0.6240 -0.4800 0.0175
Free Cash Flow 1 67.04 -2.058 97.05 -539.5 -21.95 -25.2 9.6 37.5
FCF margin 8.57% -0.23% 8.13% -97.12% -3.3% -3.58% 1.29% 4.75%
FCF Conversion (EBITDA) 52.34% - 39.48% - - - 11.79% 32.22%
FCF Conversion (Net income) 15.31% - 87.63% - - - - 420.99%
Dividend per Share 2 0.4000 0.4000 0.4000 0.1000 - - - -
Announcement Date 11/6/19 11/10/20 11/10/21 11/14/22 11/13/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Settembre 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 342 139.7 145.5 132.7 137.6 178.4 148.4 165.9 172.4 154.3 159.9 187.7 202 183 169.8
EBITDA 1 27.87 19.82 19.4 13.83 9.452 11.97 -2.4 12.89 7.943 4.555 7.256 16.88 21.59 20.01 16.43
EBIT 1 11.22 12.23 9.701 4.461 2.07 -0.04 -13.27 -1.056 -0.896 -8.707 -6.899 2.85 7.571 6.155 2.548
Operating Margin 3.28% 8.76% 6.67% 3.36% 1.5% -0.02% -8.94% -0.64% -0.52% -5.64% -4.32% 1.52% 3.75% 3.36% 1.5%
Earnings before Tax (EBT) 1 -37.88 -1.822 -4.989 0.278 -3.4 -15.88 -5.251 -3.67 -5.637 -15.91 -11.27 -5.78 -0.6933 -3.242 -8.603
Net income 1 39.17 43.32 2,116 -9.57 -20.76 -11.24 -4.927 -1.47 3.375 -15.72 -7.799 -5.331 -1.018 -4.544 -8.418
Net margin 11.45% 31.02% 1,453.77% -7.21% -15.09% -6.3% -3.32% -0.89% 1.96% -10.19% -4.88% -2.84% -0.5% -2.48% -4.96%
EPS 2 0.2900 0.5800 28.15 -0.1300 -0.2800 -0.1500 -0.0700 -0.0200 0.0600 -0.2800 -0.1780 -0.1080 -0.0200 -0.0900 -0.1700
Dividend per Share 2 0.1000 0.1000 0.1000 - - - - - - - - - - - -
Announcement Date 11/10/21 2/8/22 5/9/22 8/9/22 11/14/22 2/8/23 5/9/23 8/8/23 11/13/23 2/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: Settembre 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - 178 - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 67 -2.06 97.1 -539 -21.9 -25.2 9.6 37.5
ROE (net income / shareholders' equity) 5.99% 5.51% 8.72% - -0.48% -1.5% -0.6% 0.5%
ROA (Net income/ Total Assets) 4.26% 4.22% 6.56% - -0.43% -1.2% -0.5% 0.4%
Assets 1 10,271 1,538 1,689 - 3,301 2,289 3,465 2,227
Book Value Per Share 2 15.80 16.40 17.80 44.80 43.80 39.10 42.00 41.20
Cash Flow per Share 2 1.260 0.5100 2.010 - 0.2600 1.080 1.680 2.220
Capex 1 23.9 39.9 52.8 73.4 39.4 48.1 58.4 61.5
Capex / Sales 3.05% 4.45% 4.42% 13.22% 5.93% 6.83% 7.86% 7.79%
Announcement Date 11/6/19 11/10/20 11/10/21 11/14/22 11/13/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Azenta, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
52.18 USD
Average target price
66.8 USD
Spread / Average Target
+28.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AZENTA, INC. Stock Azenta, Inc.
-19.90% 2.91B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AZTA Stock
  4. Financials Azenta, Inc.